Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05583058
Other study ID # HODM-TGNC-C-01O
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 15, 2022
Est. completion date March 30, 2029

Study information

Verified date October 2022
Source Xiamen University
Contact Ben-tuo Zeng
Phone +86-18990938417
Email zengbentuoxmu@outlook.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The investigators propose to investigate the definition of hormone overdose and misuse (HODM) in Chinese transgender and gender nonconforming population (TGNCs), address the incidence of HODM in Chinese TGNC population, related factors and risks, identify the probable causes of HODM, and follow up HODM individuals to explore long-term effects. The research questions are: Q1 What is the definition and the criteria of HODM in Chinese TGNC population? Q2 What is the prevalence of HODM in Chinese TGNC population? Q3 What factors and risks are relevant to HODM? Q4 What are the causes? Q5 What are the long-term effects of HODM in Chinese TGNC population, compared to those who enroll in regular GAHT regimens? The investigators decide to employ a mixed-methods design to construct a full research framework on HODM. A prospective cohort study is a component of the study. The study can be divided into four stages to address research questions. Stage I will establish a precise definition and eligibility criteria of HODM through expert panel meeting and stakeholder engagement. Subsequently, a cross-sectional study will be conducted to evaluate the rate, subtypes, and related factors of HODM in Chinese TGNCs. In Stage III, semi-structured interviews and focus groups for TGNCs who are identified as HODM will be employed to investigate the causes, motivations and personal impact factors. This stage will be divided into two phases, Stage III-a before the cross-sectional study to provide a brief picture of HODM behaviors, and Stage III-b after the cross-sectional study to draw an overall pattern. Lastly, all participants of Stage II or III who would like to participate in our follow-up will be included in prospective cohorts to assess long-term effects. Among the stages, the cohort study is the subject of the registration. The investigators propose two cohorts in the study. Participants who are identified as HODM will be assigned to cohort 1 [HODM cohort], and those who are identified as regular GAHT use will be assigned to cohort 2 [non-HODM cohort]. Participants will be asked to report their gender-related and hormone use-related conditions, and mental health-related conditions at specific timepoints. The investigators will compare the HODM cohort to the non-HODM cohort to see if the overall incidence of adverse effects, gender-related, hormone-related, and mental health-related conditions differ in the cohorts.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 260
Est. completion date March 30, 2029
Est. primary completion date June 30, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - Individuals with Chinese nationality (excluding Hong Kong SAR, Macau SAR, and Taiwan). - Aged over 12. - Identify themselves as TGNCs of any subtypes, including transgender female, transgender male, genderqueer, gender non-binary, crossdresser, or other subtypes. - have experienced at least one month of GAHT of any regimens and frequency in the last one year, or is taking hormones during the period of the study. - Hormones taken include androgen, estrogen, progesterone, anti-androgen, and anti-estrogen of any chemical structures, trade names, or regimens. Exclusion Criteria: - Individuals who undertake GAHT in the absence of self-consciousness due to mental disorders, or under external coercion/abuse. - Refuse to sign or unable to understand the informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Hormone Overdose and Misuse
This is an observational study. Hormone Overdose and Misuse is an exposure.

Locations

Country Name City State
China School of Medicine, Xiamen University Xiamen Fujian

Sponsors (3)

Lead Sponsor Collaborator
Xiamen University Tongji University, Tsinghua University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 1 month from the baseline assessment
Other Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 3 months from the baseline assessment
Other Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 6 months from the baseline assessment
Other Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 12 months from the baseline assessment
Other Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 18 months from the baseline assessment
Other Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 30 months from the baseline assessment
Other Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 36 months from the baseline assessment
Other Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 42 months from the baseline assessment
Other Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 48 months from the baseline assessment
Other Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 54 months from the baseline assessment
Other GAHT attrition Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. 6 months from the baseline assessment
Other GAHT attrition Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. 12 months from the baseline assessment
Other GAHT attrition Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. 18 months from the baseline assessment
Other GAHT attrition Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. 30 months from the baseline assessment
Other GAHT attrition Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. 36 months from the baseline assessment
Other GAHT attrition Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. 42 months from the baseline assessment
Other GAHT attrition Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. 48 months from the baseline assessment
Other GAHT attrition Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. 54 months from the baseline assessment
Other Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 3 months from the baseline assessment
Other Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 6 months from the baseline assessment
Other Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 12 months from the baseline assessment
Other Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 18 months from the baseline assessment
Other Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 30 months from the baseline assessment
Other Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 36 months from the baseline assessment
Other Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 42 months from the baseline assessment
Other Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 48 months from the baseline assessment
Other Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 54 months from the baseline assessment
Other Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 1 month from the baseline assessment
Other Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 3 months from the baseline assessment
Other Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 6 months from the baseline assessment
Other Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 18 months from the baseline assessment
Other Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 30 months from the baseline assessment
Other Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 42 months from the baseline assessment
Other Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 48 months from the baseline assessment
Other Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 54 months from the baseline assessment
Other Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 1 month from the baseline assessment
Other Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 3 months from the baseline assessment
Other Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 6 months from the baseline assessment
Other Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 18 months from the baseline assessment
Other Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 30 months from the baseline assessment
Other Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 42 months from the baseline assessment
Other Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 48 months from the baseline assessment
Other Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 54 months from the baseline assessment
Other General quality of life Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. 6 months from the baseline assessment
Other General quality of life Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. 12 months from the baseline assessment
Other General quality of life Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. 18 months from the baseline assessment
Other General quality of life Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. 30 months from the baseline assessment
Other General quality of life Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. 36 months from the baseline assessment
Other General quality of life Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. 42 months from the baseline assessment
Other General quality of life Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. 48 months from the baseline assessment
Other General quality of life Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. 54 months from the baseline assessment
Other Body image Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. 6 months from the baseline assessment
Other Body image Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. 12 months from the baseline assessment
Other Body image Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. 18 months from the baseline assessment
Other Body image Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. 30 months from the baseline assessment
Other Body image Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. 36 months from the baseline assessment
Other Body image Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. 42 months from the baseline assessment
Other Body image Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. 48 months from the baseline assessment
Other Body image Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. 54 months from the baseline assessment
Other Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 3 months from the baseline assessment
Other Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 6 months from the baseline assessment
Other Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 12 months from the baseline assessment
Other Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 18 months from the baseline assessment
Other Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 30 months from the baseline assessment
Other Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 36 months from the baseline assessment
Other Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 42 months from the baseline assessment
Other Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 48 months from the baseline assessment
Other Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 54 months from the baseline assessment
Other Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 3 months from the baseline assessment
Other Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 6 months from the baseline assessment
Other Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 18 months from the baseline assessment
Other Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 30 months from the baseline assessment
Other Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 42 months from the baseline assessment
Other Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 48 months from the baseline assessment
Other Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 54 months from the baseline assessment
Other Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 60 months from the baseline assessment
Other Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 3 months from the baseline assessment
Other Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 6 months from the baseline assessment
Other Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 12 months from the baseline assessment
Other Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 18 months from the baseline assessment
Other Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 30 months from the baseline assessment
Other Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 36 months from the baseline assessment
Other Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 42 months from the baseline assessment
Other Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 48 months from the baseline assessment
Other Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 54 months from the baseline assessment
Primary Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 24 months from the baseline assessment
Primary Moderate-to-severe adverse events Any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CTCAE v5.0 grades adverse effects as from grade 1 (asymptomatic or mild) to grade 5 (death). 60 months from the baseline assessment
Secondary GAHT attrition Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. 24 months from the baseline assessment
Secondary GAHT attrition Gender affirming hormone treatment attrition due to moderate-to-severe adverse events [any adverse events of Grade 2 or higher in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0]. 60 months from the baseline assessment
Secondary Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 24 months from the baseline assessment
Secondary Gender dysphoria Gender dysphoria, evaluated using Utrecht Gender Dysphoria Scale - Gender Spectrum (UGDS-GS). UGDS-GS scores range from 18 to 90, and higher scores indicate higher levels of gender dysphoria. 60 months from the baseline assessment
Secondary Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 12 months from the baseline assessment
Secondary Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 24 months from the baseline assessment
Secondary Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 36 months from the baseline assessment
Secondary Depression Depression, evaluated using Patient Health Questionnaire-9 (PHQ-9) scale. PHQ-9 scores range from 0 to 27, and higher scores indicate higher levels of depression. 60 months from the baseline assessment
Secondary Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 12 months from the baseline assessment
Secondary Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 24 months from the baseline assessment
Secondary Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 36 months from the baseline assessment
Secondary Anxiety Anxiety, evaluated using General Anxiety Disorder-7 (GAD-7) scale. GAD-7 scores range from 0 to 27, and higher scores indicate higher levels of anxiety. 60 months from the baseline assessment
Secondary General quality of life Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. 24 months from the baseline assessment
Secondary General quality of life Quality of life, using 36-Item Short Form Survey (SF-36) scale. SF-36 scores range from 0 to 100, and higher scores indicate better quality of life. 60 months from the baseline assessment
Secondary Body image Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. 24 months from the baseline assessment
Secondary Body image Body image, using Body Image States Scale (BISS). BISS scores range from 6 to 54, and higher scores indicate worse body images. 60 months from the baseline assessment
Secondary Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 24 months from the baseline assessment
Secondary Body-gender congruence Body-gender congruence, evaluated using Transgender Congruence Scale (TCS). TCS scores range from 1 to 5 (or 12 to 60), and higher scores indicate better gender congruence. 60 months from the baseline assessment
Secondary Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 12 months from the baseline assessment
Secondary Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 24 months from the baseline assessment
Secondary Tanner stage Tanner stages, evaluated using Visual Analogue Scale and Tanner Stage figures. Tanner stages divide the puberty process into 5 stages (stage 1 to stage 5), and higher stages indicate higher levels of puberty. 36 months from the baseline assessment
Secondary Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 24 months from the baseline assessment
Secondary Gender identity Gender identity, evaluated using Visual Analogue Scale, ranging from 0% female to 100% female. This score does not indicate any better or worse conditions. 60 months from the baseline assessment
See also
  Status Clinical Trial Phase
Recruiting NCT06098781 - Gynaecological Gender-affirming Surgeries
Recruiting NCT04064671 - ZEPHYR: A Study Evaluating Surgical Outcome After Implantation of the Zephyr ZSI 475 FTM Inflatable Penile Implant in the Neophallus After Female-to-male Sex Reassignment Surgery
Completed NCT03602222 - An LGBT-Competency Program for Mental Health Professionals in Romania N/A
Completed NCT04708600 - Effectiveness of Speech Therapy in Trans Women. N/A
Completed NCT04195659 - Chest Dysphoria in Transmasculine Spectrum Adolescents
Not yet recruiting NCT05903911 - Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria N/A
Not yet recruiting NCT04265885 - Gender Dysphoria and Transition
Not yet recruiting NCT04160364 - Gender Dysphoria in Children and Adolescents : Parents' Perspectives
Recruiting NCT06245681 - Effects of Cross-sex Hormone Treatment on Cardiac Function, Myocardial and Hepatic Fat Content
Active, not recruiting NCT05489159 - Sleep and IR in Transgender Adolescents
Recruiting NCT04736797 - Transition in Transgender
Recruiting NCT04979338 - Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries Phase 3
Recruiting NCT05829928 - Testicular Tissue Cryopreservation in the Setting of Gender-Affirming Therapy
Recruiting NCT04993469 - Patient Reported Outcome on Genital Sensitivity and Sexual Function After Genital Gender Affirming Surgery N/A
Recruiting NCT05884307 - Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria N/A
Recruiting NCT05883553 - Epithesis Versus Prosthesis in Post-phalloplasty Transgender Patients. N/A
Completed NCT04290286 - i2TransHealth: Interdisciplinary, Internet-based Trans Health Care N/A
Terminated NCT03078829 - The Relation of GnRH Treatment to QTc Interval in Transgender Females
Recruiting NCT05649605 - Early Mental Response - The EMRE Study N/A
Recruiting NCT05204732 - Acoustic and Perceptual Effects of Intonation Training in Gender Diverse People N/A

External Links